MAM
MRSN

Meeder Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Meeder Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-390
Closed -$181K – 2088
2020
Q3 		$181K Hold
390
– – 0.01% 635
2020
Q2 		$228K Buy
390
+170
+77% +$58.1K 0.01% 568
2020
Q1 		$32K Buy
220
+164
+293% +$28.7K ﹤0.01% 1068
2019
Q4 		$8K Sell
56
-24
-30% -$1.75K ﹤0.01% 1633
2019
Q3 		$3K Buy
80
+67
+515% +$4.87K ﹤0.01% 1884
2019
Q2 		$1K Buy
13
+1
+8% +$118 ﹤0.01% 1961
2019
Q1 		$2K Buy
+12
New +$1.51K ﹤0.01% 1561
2018
Q1 		– Sell
-1
Closed – – 1672
2017
Q4 		$0 Buy
+1
New +$436 ﹤0.01% 1742

Other funds holding MRSN

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return